ライフサイエンスコーパス: immunomodulatory agent

1 inform the application of minocycline as an immunomodulatory agent.

2 otential role for bilirubin as an endogenous immunomodulatory agent.

3 ndirect antioxidant, as well as an important immunomodulatory agent.

4 internalization, making them effective TLR-9 immunomodulatory agents.

5 when combined with proteasome inhibitors and immunomodulatory agents.

6 antibacterial, antimalarial, anticancer, and immunomodulatory agents.

7 inical trials have reinvigorated interest in immunomodulatory agents.

8 , a risk that is increased by treatment with immunomodulatory agents.

9 are in development as antiproliferatives or immunomodulatory agents.

10 application of these compounds as potential immunomodulatory agents.

11 nsights for the use of cysteine proteases as immunomodulatory agents.

12 These compounds may represent promising immunomodulatory agents.

13 ted in combination therapy trials with other immunomodulatory agents.

14 ystem agents, herbal/dietary supplements and immunomodulatory agents.

15 by which IMiDs drugs function as therapeutic immunomodulatory agents.

16 ing agents, have recently been identified as immunomodulatory agents.

17 that has also been used to test a number of immunomodulatory agents.

18 infection to combined antiviral and specific immunomodulatory agents.

19 sible adverse effects of this combination of immunomodulatory agents.

20 ults indicate that anti-CD45 mAbs are potent immunomodulatory agents, able to sustain indefinite isle

21 D) have focused largely on the use of single immunomodulatory agents administered within 100 days of

22 However, these broad immunomodulatory agents, already limited by their side e

23 Newer immunomodulatory agents also are being explored in pedia

24 se treatments, including corticosteroids and immunomodulatory agents, although often effective, can h

25 study provides a framework to identify novel immunomodulatory agents and to prioritize compounds for

26 cancer vaccines, adoptive T-cell therapy and immunomodulatory agents and will summarize the immune ef

27 prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease pr

28 and second-generation proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies.

29 that tested the efficacy of a combination of immunomodulatory agents, anti-thymocyte globulin and peg

30 b, mammalian target of rapamycin inhibitors, immunomodulatory agents, antibodies and cyclin pathway-d

31 er acetate (GA), a parenterally administered immunomodulatory agent approved for MS treatment, we tes

32 sis is 0.05% cyclosporine A and is the first immunomodulatory agent approved for treatment of dry eye

33 Data for efficacy of other oral immunomodulatory agents are based primarily on case repo

34 and steroids as inductive agents and use of immunomodulatory agents as maintenance therapies.

35 Immunomodulatory agents attempt to increase the efficacy

36 unicable diseases with good safety profiles, immunomodulatory agents, biologics (eg monoclonal antibo

37 Thus, IFN-lambda acted as a unique immunomodulatory agent by modifying transcriptional and

38 ay of treatment, other immunosuppressive and immunomodulatory agents can be used in the multi-modalit

39 New immunomodulatory agents currently being tested in contro

40 VHD are reviewed with particular emphasis on immunomodulatory agents currently incorporated into clin

41 The efficacy of the anti-cancer immunomodulatory agent cyclophosphamide (CTX) relies on

42 warrants further examination as a potential immunomodulatory agent for human disease.

43 nale for the use of 2ME2 as a tolerable oral immunomodulatory agent for the treatment of autoimmune d

44 Lenalidomide is an active immunomodulatory agent for the treatment of myelodysplas

45 Glatiramer acetate (GA) has been used as an immunomodulatory agent for the treatment of relapsing-re

46 xt, it may also have potential utility as an immunomodulatory agent for transplantation.

47 iNKT cells) are being developed as potential immunomodulatory agents for a variety of applications.

48 hropoiesis-stimulating agents, androgens, or immunomodulatory agents for anemia, cytoreductive drugs

49 idney transplants, and individuals receiving immunomodulatory agents for autoimmune and inflammatory

50 t that n-3 PUFAs may be clinically useful as immunomodulatory agents for demyelinating diseases throu

51 adenoviruses expressing cytokines as potent immunomodulatory agents for the generation of protective

52 d adalimumab can be considered as first-line immunomodulatory agents for the treatment of ocular mani

53 b can be considered as potential second-line immunomodulatory agents for the treatment of severe ocul

54 adalimumab can be considered as second-line immunomodulatory agents for the treatment of uveitis ass

55 An azido group was incorporated into the immunomodulatory agent FTY720, accomplishing the first s

56 g the Toll-like receptor (TLR) pathway using immunomodulatory agent GIT27.

57 eutic response using the currently available immunomodulatory agents has not yet been achieved.

58 Lenalidomide, an immunomodulatory agent, has shown activity in DLBCL.

59 st decade, a number of immunosuppressive and immunomodulatory agents have been approved for the treat

60 Immunomodulatory agents (IMiDs) target not only MM cells

61 yeloma (MM), including alkylators, steroids, immunomodulatory agents (IMiDs), proteasome inhibitors (

62 mary immunodeficiency diseases as well as an immunomodulatory agent in a variety of autoimmune and in

63 oactive properties, is well recognized as an immunomodulatory agent in allergic and inflammatory reac

64 Bortezomib is a promising novel immunomodulatory agent in allogeneic transplantation.

65 system and is regarded as a highly promising immunomodulatory agent in cancer therapy.

66 as been used as a preventive and therapeutic immunomodulatory agent in several animal species.

67 hance antitumor immune responses using novel immunomodulatory agents in combination with standard of

68 ct a fundamental role for these receptors as immunomodulatory agents in normal and subverted B lineag

69 Standard immunomodulatory agents including steroids, intravenous

70 of systemic and topical anti-inflammatory or immunomodulatory agents, including prednisolone acetate,

71 s are augmented by the administration of the immunomodulatory agent interleukin (IL)-2.

72 Lenalidomide, an immunomodulatory agent, is effective as monotherapy for

73 for minocycline as an anti-inflammatory and immunomodulatory agent, its utility in the treatment of

74 These results suggest that immunomodulatory agents may provide a treatment option f

75 ients when CD38 antibodies are combined with immunomodulatory agents or proteasome inhibitors.

76 Immunomodulatory agents potentially represent a new clas

77 purine metabolic pathway (e.g. forodesine), immunomodulatory agents, proapoptotic small molecules (e

78 Immunomodulatory agents recently examined in patients wi

79 In combination with currently available immunomodulatory agents, SFK inhibition could potentiall

80 Numerous immunomodulatory agents showing promise in preclinical s

81 eptides to autoreactive T cells or to direct immunomodulatory agents such as interleukins or cytolyti

82 complex mechanisms of action of pleiotropic immunomodulatory agents, such as glucocorticoids, vitami

83 Recently, immunomodulatory agents, such as immune checkpoint inhib

84 Novel immunomodulatory agents, such as infliximab, have shown

85 Immunomodulatory agents, such as steroids, plasmapheresi

86 New active drugs include immunomodulatory agents, such as thalidomide and CC-5013

87 ht thus be expanded with its use as a potent immunomodulatory agent targeting Treg in cancer immunoth

88 as mycophenolate mofetil and a new class of immunomodulatory agents targeting cytokines, in particul

89 Lenalidomide, an immunomodulatory agent that enhances antibody-dependent

90 ren, NJ) is a putative anti-angiogenesis and immunomodulatory agent that has demonstrated activity in

91 Atorvastatin is a potent immunomodulatory agent that holds promise as a novel and

92 FTY720 is a novel immunomodulatory agent that inhibits lymphocyte traffick

93 Bz-423 is a novel immunomodulatory agent that is active against disease ev

94 ug against tumor cells, but also as a potent immunomodulatory agent that selectively impairs MDSC-ind

95 the treatment of immune-mediated diseases by immunomodulatory agents that alter the cytokine milieu i

96 Development of immunomodulatory agents that enhance innate immune respo

97 tic and antibiotic sparing roles for vaginal immunomodulatory agents that specifically target HDP ind

98 al uses general (rather than tumor-specific) immunomodulatory agents to boost the number and activity

99 1D progression and monitoring the ability of immunomodulatory agents to clear insulitis.

100 Thalidomide (THD) is an immunomodulatory agent used to treat immune-mediated dis

101 Pegylated interferon alfa-2a is an immunomodulatory agent used to treat polycythemia vera.

102 Glucocorticoids continue to be the major immunomodulatory agents used in clinical medicine today.

103 ed only moderate efficacy for any particular immunomodulatory agent, whereas new data have confirmed

104 pathways and into the biological effects of immunomodulatory agents will help to optimize or adopt t

105 the safety and efficacy of lenalidomide, an immunomodulatory agent with anti-angiogenic properties,

106 Lenalidomide is a novel immunomodulatory agent with antiproliferative activities

107 Lenalidomide is an immunomodulatory agent with biological activity in sever

108 Lenalidomide is an immunomodulatory agent with proven tumoricidal and antip

109 Lenalidomide is an immunomodulatory agent with therapeutic activity in chro